Latest
30
May
Rethinking Biotech Financing
At the recent Capital for Cures gathering in Milan, a curated group of biotech innovators, investors, and family office leaders
4 min read
28
May
How Europe Can Compete in the Global Biotech Race: Lessons from the Capital for Cures Event Series
If biotech were a footrace, Europe would be the competitor with flawless running shoes, world-class muscle tone—and one leg
3 min read
27
May
The Mansion House Accord: Reinvigorating UK Investment or Merely Rebadging the Status Quo?
In July 2023, the United Kingdom government launched the Mansion House Compact, a voluntary commitment by nine of the country’
4 min read
26
May
Whither ESG? The Curious Case of Pharma's Forgotten Acronym
Ah, ESG! Not long ago, you could hardly sip your oat milk latte—or endure a quarterly earnings call—without
3 min read
25
May
Health Economics: Pharma’s Favorite Crystal Ball
Health economics is to pharma what a crystal ball is to a fortune teller—draped in mystique, full of promise,
3 min read
24
May
ICER: The Gatekeeper of European Healthcare, or a Flawed Oracle?
The Incremental Cost-Effectiveness Ratio (ICER) is the darling of health economists and the bane of pharmaceutical companies. At its heart,
3 min read
23
May
In a Hole in the Budget There Lived a KOL
Not a nasty, dirty, wet hole, nor yet a humble one. This was a suite at the Four Seasons, with
3 min read
22
May
The Problem with Markov Models
Markov models have become a default tool in drug development, used for modeling disease progression, treatment outcomes, and cost-effectiveness. While
3 min read
21
May
AI in Biotech: Taking Stock of a Decade of Progress and the Challenges Ahead
Artificial intelligence has had a profound decade in biotech, advancing from a promising academic endeavor to a critical driver of
3 min read
20
May
The Problem with Optimism Bias in Biotech Projections: A Quantitative and Probabilistic Analysis
Optimism bias, the cognitive tendency to overestimate the likelihood of favorable outcomes and underestimate risks, is a pervasive issue in
3 min read